| 产品名称： | Rotavirus reassortant |
|---|---|
| 商品货号： | TS203125 |
| Classification： | Reoviridae, Rotavirus |
| Agent： | Rotavirus reassortant |
| Strain： | WI79-4 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | reassortant of WI79, isolated from a human infant, and WC3, isolated from a calf |
| Product Format： | frozen |
| Storage Conditions： | -70°C |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Comments： | reassortant of WI79, isolated from a human infant, and WC3, isolated from a calf -70C |
| Effect on Host： | Yes, in vitro effects: Cytopathic effects (cell rounding and shedding of cells) CPE is cell rounding and shedding of cells |
| Recommended Host： | Vero cells (ATCC CCL-81) Host of Choice: Vero cells (ATCC CRL-81) Host Range: Vero, CV-1, MA-104 MA-104 cells (ATCC CRL-2378); CV-1 cells (ATCC CCL-70); Vero cells (ATCC CCL-81) |
| Growth Conditions： | Temperature: 36.0°C Duration: 1-4 days at 37C |
| Cryopreservation： | Storage temperature: -70C |
| Name of Depositor： | Wistar Institute of Anatomy and Biology |
| U.S. Patent： | |
| U.S. Patent Number： | |
| Special Collection： | NCRR Contract |
| References： | Clark HF, et al. Rotavirus reassortant vaccine. US Patent 5,626,851 dated May 6 1997 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Rotavirus reassortant |
|---|---|
| 商品货号： | TS203125 |
| Classification： | Reoviridae, Rotavirus |
| Agent： | Rotavirus reassortant |
| Strain： | WI79-4 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | reassortant of WI79, isolated from a human infant, and WC3, isolated from a calf |
| Product Format： | frozen |
| Storage Conditions： | -70°C |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Comments： | reassortant of WI79, isolated from a human infant, and WC3, isolated from a calf -70C |
| Effect on Host： | Yes, in vitro effects: Cytopathic effects (cell rounding and shedding of cells) CPE is cell rounding and shedding of cells |
| Recommended Host： | Vero cells (ATCC CCL-81) Host of Choice: Vero cells (ATCC CRL-81) Host Range: Vero, CV-1, MA-104 MA-104 cells (ATCC CRL-2378); CV-1 cells (ATCC CCL-70); Vero cells (ATCC CCL-81) |
| Growth Conditions： | Temperature: 36.0°C Duration: 1-4 days at 37C |
| Cryopreservation： | Storage temperature: -70C |
| Name of Depositor： | Wistar Institute of Anatomy and Biology |
| U.S. Patent： | |
| U.S. Patent Number： | |
| Special Collection： | NCRR Contract |
| References： | Clark HF, et al. Rotavirus reassortant vaccine. US Patent 5,626,851 dated May 6 1997 |
